Daniel Hornan
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Ophthalmology top 2%
- Glaucoma and retinal disorders
Papers in
-
- Glaucoma and retinal disorders 4
-
- COVID-19 Clinical Research Studies 5
- Partner nations
- United KingdomGreeceVietnam
In The Last Decade
Daniel Hornan
9 papers receiving 1.4k citations
Daniel Hornan's Hit Papers
Peers
Comparison fields: 5 of 47
- Infectious Diseases 744
- Ophthalmology 218
- Internal Medicine 15
- Family Practice 5
- Obstetrics and Gynecology 17
Countries citing papers authored by Daniel Hornan
This map shows the geographic impact of Daniel Hornan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Hornan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Hornan more than expected).
Fields of papers citing papers by Daniel Hornan
This network shows the impact of papers produced by Daniel Hornan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Hornan. The network helps show where Daniel Hornan may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 2 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 3 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 4 | 2021 | 213 | |
| 5 | Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial Hit paper breakdown → | 2022 | 139 |
| 6 | 2023 | 84 | |
| 7 | 2020 | 53 | |
| 8 | 2019 | 46 | |
| 9 | 2025 | 4 |
About Daniel Hornan
Daniel Hornan is a scholar working on Ophthalmology, Infectious Diseases, Nuclear Energy and Engineering, Waste Management and Disposal and Organic Chemistry, having authored 9 papers that have together received 1.4k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (5 papers) and Glaucoma and retinal disorders (4 papers). The work is most often cited by research in Infectious Diseases (744 citations), Ophthalmology (218 citations), Internal Medicine (15 citations), Family Practice (5 citations) and Obstetrics and Gynecology (17 citations). Daniel Hornan has collaborated with scholars based in United Kingdom, Greece and Vietnam. Their work appears in journals such as The Lancet, Ophthalmology and JAMA Ophthalmology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.